海普瑞2023中期报告

(A joint stock company incorporated in the People’s Republic of China with limited liability) Stock Code: 9989 Contents目錄 Corporate Information2公司資料Financial Highlights5財務摘要Management Discussion and Analysis6管理層討論與分析Corporate Governance and Other Information Disclosed22企業管治及其他披露資料Interim Condensed Consolidated Statements of Profit or Loss39中期簡明綜合損益表Interim Condensed Consolidated Statements of Comprehensive Income40中期簡明綜合全面收益表Interim Condensed Consolidated Statements of Financial Position41中期簡明綜合財務狀況表Interim Condensed Consolidated Statements of Changes in Equity43中期簡明綜合權益變動表Interim Condensed Consolidated Statements of Cash Flows45中期簡明綜合現金流量表Notes to Interim Condensed Consolidated Financial Information49中期簡明綜合財務資料附註 Corporate Information2 董事會 Board of Directors 執行董事李鋰先生（董事長）李坦女士（副總經理）單宇先生（總經理）張平先生（於二零二三年五月二十二日委任） Executive Directors Mr. Li Li(Chairman)Ms. Li Tan(Deputy General Manager)Mr. Shan Yu(General Manager)Mr. Zhang Ping (appointed on May 22, 2023) Independent Non-executive DirectorsDr. Lu Chuan 獨立非執行董事 Mr. Huang Peng (appointed on May 22, 2023)Mr. Yi Ming (appointed on May 22, 2023)Mr. Chen Junfa (retired on May 22, 2023)Mr. Wang Zhaohui (retired on May 22, 2023) 黃鵬先生（於二零二三年五月二十二日委任）易銘先生（於二零二三年五月二十二日委任）陳俊發先生（於二零二三年五月二十二日退任）王肇輝先生（於二零二三年五月二十二日退任） Joint Company Secretaries 聯席公司秘書 錢風奇先生陳詩婷女士(ACG, HKACG) Mr. Qian FengqiMs. Chan Sze Ting(ACG, HKACG) 授權代表 錢風奇先生陳詩婷女士 Authorized Representatives Mr. Qian FengqiMs. Chan Sze Ting 監事 Supervisors 鄭澤輝先生（主席）唐海均女士蘇紀蘭女士（職工監事） Mr. Zheng Zehui(Chairman)Ms. Tang HaijunMs. Su Jilan(Employee Supervisor) 戰略委員會李鋰先生（主席）李坦女士呂川博士 Strategy Committee Mr. Li Li(Chairman)Ms. Li TanDr. Lu Chuan 薪酬與考核委員會 Remuneration and Evaluation Committee 易銘先生（主席）（於二零二三年五月二十二日委任）王肇輝先生（主席）（於二零二三年五月二十二日退任）李鋰先生黃鵬先生（於二零二三年五月二十二日委任）陳俊發先生（於二零二三年五月二十二日退任） Mr. Yi Ming(Chairman)(appointed on May 22, 2023)Mr. Wang Zhaohui(Chairman)(retired on May 22, 2023)Mr. Li LiMr. Huang Peng (appointed on May 22, 2023)Mr. Chen Junfa(retired on May 22, 2023) 審計委員會 Audit Committee Mr. Huang Peng(Chairman)(appointed on May 22, 2023)Mr. Chen Junfa(Chairman)(retired on May 22, 2023)Dr. Lu ChuanMr. Yi Ming (appointed on May 22, 2023)Mr. Wang Zhaohui (retired on May 22, 2023) 黃鵬先生（主席）（於二零二三年五月二十二日委任）陳俊發先生（主席）（於二零二三年五月二十二日退任）呂川博士易銘先生（於二零二三年五月二十二日委任）王肇輝先生（於二零二三年五月二十二日退任） 3Corporate Information 提名委員會 Nomination Committee Dr. Lu Chuan(Chairman)Mr. Li LiMr. Yi Ming (appointed on May 22, 2023)Mr. Chen Junfa (retired on May 22, 2023) 呂川博士（主席）李鋰先生易銘先生（於二零二三年五月二十二日委任）陳俊發先生（於二零二三年五月二十二日退任） Registered Office 註冊辦事處 No. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of China 中華人民共和國深圳市南山區朗山路21號 總部及中國主要營業地點 Headquarters and Principal Place of Businessin the PRC No. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of China 中華人民共和國深圳市南山區朗山路21號 香港主要營業地點 Principal Place of Business in Hong Kong Room 4724, 47th Floor, Sun Hung Kai Center30 Harbour Road, Wan ChaiHong Kong 香港灣仔港灣道30號新鴻基中心47樓4724室 Principal Banks 主要往來銀行招商銀行深圳分行中國深圳市深南大道7088號招商銀行大廈 China Merchants Bank, Shenzhen BranchChina Merchants Bank TowerNo. 7088 Shennan BoulevardShenzhen, China 中國銀行深圳分行中國深圳市羅湖區建設路2022號 Bank of China, Shenzhen Branch2022 Jianshe Road, Luohu DistrictShenzhen, China The Hongkong and Shanghai Banking Corporation Limited1 Queen’s Road CentralHong Kong 香港上海滙豐銀行有限公司香港皇后大道中1號 Corporate Information 合規顧問 Compliance Advisor Somerley Capital Limited20/F, China Building29 Queen’s Road CentralHong Kong 新百利融資有限公司香港皇后大道中29號華人行20樓 香港法律顧問安理國際律師事務所香港中環交易廣場三座9樓 Hong Kong Legal Advisor Allen & Overy9/F, Three Exchange SquareCentralHong Kong PRC Legal Advisor 中國法律顧問北京中銀（深圳）律師事務所深圳市福田區深南大道2002號中廣核大廈北樓8層 Zhong Yin (Shenzhen) Law Firm8th Floor, North Building, China Guangdong Nuclear Power Building2002 Shennan Avenue, Futian DistrictShenzhen H Share Registrar H股證券登記處 卓佳證券登記有限公司香港夏愨道16號遠東金融中心17樓 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 股票代碼A股：002399（深圳證券交易所）H股：9989（香港聯合交易所） Stock Code A Shares: 002399 (Shenzhen Stock Exchange)H Shares: 9989 (Hong Kong Stock Exchange) Website of the Company www.hepalink.com 公司網站www.hepalink.com Management Discussion and Analysis6 概覽 Overview Founded in Shenzhen in 1998, Hepalink is a leading multinational pharmaceuticalcompany with A+H dual financing platform. Our main business includes theinvestment, development and commercialization of the heparin industry chain,bio-macromolecule Contract Development and Manufacturing Organization(“CDMO”)and innovative drugs. The Group’s three business segments aresynergistic and driven by unmet clinical needs; committing to providing highquality, safe and effective drugs and services for global patients to protect theirhealth. 海普瑞於一九九八年成立於深圳，是擁有A+H雙融資平台的領先跨國製藥企業，主要業務覆蓋肝素產業鏈、生物大分子合同開發和生產組織（「CDMO」）和創新藥物的投資、開發及商業化。本集團的三大板塊業務相互協同，以臨床未滿足需求為驅動，致力於為全球患者提供高質量的安全有效藥物和服務，護佑健康。 The Group’s businesses cover the manufacture and sales of pharmaceuticalproducts, development of C